LOS ANGELES, May 20, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Senti Biosciences, Inc. ("Senti" or "the Company") (NASDAQ: SNTI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Senti announced in a press release issued on April 28, 2025, that "enrollmen ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Senti Biosciences, Inc. and its officers or directors [1] Group 1: Company Developments - On April 28, 2025, Senti announced the cessation of enrollment in the Investigator Sponsored Trial for its solid tumor pipeline product SN301A due to observed dose limiting toxicities [2] - Following this announcement, Senti's stock price dropped by $1.36 per share, representing a decline of 27.2%, closing at $3.64 per share on the same day [2] Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of advocating for victims of securities fraud and corporate misconduct [3] - The firm has a track record of recovering significant damages for class members, highlighting its expertise in handling such cases [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Senti Biosciences, Inc. and its officers or directors [1] Group 1: Company Developments - On April 28, 2025, Senti announced the cessation of enrollment in the Investigator Sponsored Trial for its solid tumor product SN301A due to observed dose limiting toxicities [3] - Following this announcement, Senti's stock price dropped by $1.36 per share, representing a 27.2% decline, closing at $3.64 per share on the same day [3] Group 2: Legal Actions - Pomerantz LLP is actively seeking claims from investors of Senti Biosciences, indicating a potential class action lawsuit [1][2] - The firm has a long history in corporate, securities, and antitrust class litigation, having recovered significant damages for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Senti Biosciences, Inc. following a significant drop in stock price due to halted clinical trials [1][3]. Group 1: Company Developments - On April 28, 2025, Senti announced the cessation of enrollment in the Investigator Sponsored Trial for its solid tumor product SN301A due to observed dose limiting toxicities [3]. - Following this announcement, Senti's stock price decreased by $1.36 per share, representing a 27.2% decline, closing at $3.64 per share [3]. Group 2: Legal Investigation - Pomerantz LLP is representing investors of Senti and is looking into claims of securities fraud or other unlawful practices by the company and its officers or directors [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action investigation [1].